Nanologica AB (OSTO:NICA) Stock Based Compensation: kr0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NICA Nanologica AB OSTO:NICA
46 GF Score
Price kr0.44
GF Value kr4.27
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Nanologica AB Stock Based Compensation?

Nanologica AB OSTO:NICA -2.84% 46 Stock Based Compensation is kr0.00 Mil as of Mar. 2026. GuruFocus rates OSTO:NICA with a GF Score™ of 46/100 and a GF Value™ of kr4.27 (Possible Value Trap). The stock has 9 warning signs investors should review.

Nanologica AB's Stock Based Compensation for the three months ended in Mar. 2026 was kr0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.00 Mil.

Nanologica AB Stock Based Compensation Related Terms

Nanologica AB Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Nanologica AB's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB Stock Based Compensation Chart

Nanologica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nanologica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:NICA
46GF Score
Nanologica AB OSTO:NICA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanologica AB Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

What does a Stock Based Compensation of kr0.00 Mil mean?
Nanologica AB (OSTO:NICA) has a Stock Based Compensation of kr0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Nanologica AB and its competitors.
Is Nanologica AB's Stock Based Compensation too high?
Nanologica AB's current Stock Based Compensation is kr0.00 Mil. Overall, Nanologica AB has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Stock Based Compensation compare to VRTX and REGN?
Nanologica AB's Stock Based Compensation of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Nanologica AB and its competitors. Nanologica AB's current Stock Based Compensation is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.27, compared to a current price of kr0.44 — trading 89.6% below its estimated fair value. The current Stock Based Compensation is kr0.00 Mil. Nanologica AB's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current Stock Based Compensation is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanologica AB (OSTO:NICA) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of kr0.44 is trading 89.6% below its estimated GF Value™ of kr4.27. GuruFocus considers Nanologica AB to be Possible Value Trap.

Key valuation signals for OSTO:NICA:

  • Stock Based Compensation: kr0.00 Mil
  • GF Value™: kr4.27 vs. price of kr0.44 (89.6% below fair value)
  • GF Score™: 46/100 with 9 warning signs

No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nanologica AB Business Description

Other Exchanges 4YD:Germany
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score

Get the complete analysis for OSTO:NICA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.44
Price
kr4.27
GF Value